Eviplera is a fixed-dose tablet combining 25mg rilpivirine, 200mg FTC (emtricitabine), and 245mg tenofovir, manufactured jointly by Johnson & Johnson/Tibotec and Gilead Sciences.

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), FTC is a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir is a nucleotide reverse transcriptase inhibitor (NtRTI). These drugs reduce the amount of HIV in the body and prevent the development of AIDS-defining illnesses.

The standard dose of Eviplera is one purplish-pink tablet once a day. The manufacturers advise patients to take the tablet with food (the original advice was that it should be taken with a meal, but further research suggests that a 'light meal' is sufficient).

Eviplera is the second combination tablet to be licensed for use in Europe and the United States that provides all the drugs needed for an anti-HIV regimen, in one tablet, once a day. It was licensed in the United States for use in HIV-positive adults in August 2011 and approved for use in the European Union in November 2011.

In the European Union Eviplera is licensed for use in patients with a viral load less than or equal to 100,000 copies/ml.

For more information on Eviplera's component drugs, including drug interactions, side-effects and resistance, see rilpivirine (Edurant), FTC (emtricitabine, Emtriva) and tenofovir (Viread).

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.